Recovery Peptide Safety (BPC-157, TB-500)
Safety considerations for the unapproved recovery peptides BPC-157 and TB-500. What the published reviews actually report, and why the human evidence base is too thin to support safety claims.
Safety Overview
BPC-157 lacks US Food and Drug Administration approval. A 2025 systematic review in HSS Journal describes it as used by clinicians and athletes “[d]espite lacking US Food and Drug Administration approval and its use being banned in professional sports.” A 2025 narrative review reaches the same conclusion: until well-designed clinical trials are conducted, “BPC-157 should be considered investigational, and its use approached with caution.”
TB-500 is not thymosin beta-4 itself. Analytical chemists at the Ghent University doping-control laboratory reported the identification of Ac-LKKTETQ — the N-terminal acetylated 17-23 fragment of human thymosin beta-4 — in TB-500. Evidence generated with the full protein does not automatically transfer to a seven-residue fragment of it.
What the Human Evidence Base Actually Contains
Two 2025 reviews each counted the human dataset for BPC-157, and they arrived at different numbers under different inclusion criteria — one counting 1 clinical study among 36 included, the other describing 3 pilot studies. Neither claims agreement with the other, and the gap is itself informative about how thin and how loosely bounded this literature is:
| Finding | Source |
|---|---|
| 36 studies included: 35 preclinical, 1 clinical | HSS Journal systematic review, 2025 |
| ”No clinical safety data were found” | HSS Journal systematic review, 2025 |
| ”Only three pilot studies have examined BPC-157 in humans” | Current Reviews in Musculoskeletal Medicine, 2025 |
| ”No adverse effects were reported, but rigorous, large-scale trials are lacking” | Current Reviews in Musculoskeletal Medicine, 2025 |
The three human pilot studies covered intra-articular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics. Neither review claims its count is exhaustive: the HSS Journal figure reflects a systematic search closing 3 June 2024 under that review’s own inclusion criteria, and the Current Reviews paper says only that three pilot studies “have examined” the compound.
For thymosin beta-4, the parent protein has gone further. It “accelerated the rate of repair in phase 2 trials with patients having pressure ulcers, stasis ulcers, and epidermolysis bullosa wounds.” Those trials tested the protein, not the TB-500 fragment.
Mechanism — Established in Animals
The narrative review reports that BPC-157 “activates several overlapping pathways, notably VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis, promoting angiogenesis, fibroblast activity, and neuromuscular stabilization.” The systematic review adds that it “enhances growth hormone receptor expression and several pathways involved in cell growth and angiogenesis, while reducing inflammatory cytokines.”
Both descriptions come from animal models. The systematic review’s preclinical safety finding — “no adverse effects across several organ systems” — is likewise animal data, and sits alongside the same review’s statement that no clinical safety data exist.
Thymosin beta-4 was “found to have angiogenic and antiinflammatory activity” and increases dermal healing rates “in various preclinical animal models, including diabetic and aged animals.”
Product Quality Risks
The systematic review states the risk directly: “Adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety.” The narrative review notes BPC-157’s “wide availability through non-regulated sources.”
Sport and Anti-Doping Status
The HSS Journal review describes BPC-157’s “use being banned in professional sports,” and recommends “that clinicians counsel athletes to understand their organizations’ rules to remain compliant with medication/supplement safety and testing standards.”
TB-500 has been the subject of anti-doping method development since 2012. The Ghent paper opens: “The formulation TB-500 is suspected to be used as doping agent in sport,” and describes detection strategies in plasma and urine for what it calls “the N-terminal acetylated 17-23 fragment of human thymosin beta 4”. The paper does not characterise that fragment as active — a distinction this page’s own argument depends on.
The Evidence Problem in One Line
BPC-157 has 35 preclinical studies for every clinical one, and no clinical safety data at all. For TB-500, none of the sources cited on this page evaluates a human evidence base: the anti-doping paper is analytical method development, and the Vitamins and Hormones chapter concerns the parent protein thymosin beta-4 rather than the fragment sold under that name.
These peptides are not FDA-approved. Safety is unknown. This is for educational purposes only.
Sources & Citations
- 1
- 2journalRegeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
pmid-40789979
- 4
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.